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Background: Protect II study evaluated the effect of circulatory support with Impella vs
Intra aortic balloon pump (IABP) in high risk patients undergoing high risk PCI with
depressed LV function and complex anatomy. The results of the study were confounded
by an imbalanced and more vigorous use of rotational atherectomy(RA) in the Impella
arm which made the interpretation of the composite endpoint difficult. We sought to
evaluate the safety and effectiveness of Impella 2.5 in high risk percutaneous coronary
intervention (HRPCI) compared to the IABP in a more homogeneous population, without
the confounding effect of RA.
Methods: A total of 375 eligible patients underwent HRPCI without the use of rotational
atherectomy (88% Protect II study). A composite of 10 major adverse events (MAE)
endpoint including death, myocardial infarction, stroke, any repeat revascularization, was
assessed at 30 and 90 days.
Results: Baseline and procedural characteristics were balanced between the study arms: age
67 10 years old, 86% CHF, 51% diabetes, 67% had prior myocardial infarction, and 26%
renal insufficiency. The LVEF was 246, STS mortality was 5.66 and Syntax was 2912.
Patients treated with the Impella device had significant improved outcomes at 30 day and 90
day compared to IABP arm ( 29.3% vs 41.9%, p0.011 and 35.5% vs 50.5%, p0.003).
Conclusions: Patients undergoing high risk PCI supported with Impella had superior
outcomes compared to those with IABP.
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Background: We evaluated the impact of paclitaxel-coated balloon angioplasty for
treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty
alone. (NCT00998439).
Methods: In this prospective, single-blind, multicenter, trial we randomly assigned 110
patients with Instent-Restnosis of drug eluting stents to undergo treatment either with paclitaxel
coated balloon (SeQuent Please, BBraun, Melsungen) or balloon angioplasty alone. Primary
endpoint was in-stent late lumen loss at 6 months. Secondary clinical endpoint was composited
of cardiac death, myocardial infarction attributed to the target vessel or TLR.
Results: There was no difference in patient baseline characteristics. Lesion length was
11.26.5mm in the DCB- and 12.28.2mm in the POBA-group (pn.s). Post PCI, for
the stented segment and the total segment minimal lumen diameter and diameter stenosis
were not different. Clinical follow-up after 12 months was 100%. Treatment with DCB
was superior to balloon angioplasty alone with an in-stent late loss of 0.430.61mm vs.
1.030.77mm (p0.001). Minimal lumen diameter was significantly larger and percent
diameter stenosis significantly lower with use of the DCB for both the stented and total
segment. Restenosis rate was reduced from 58.1% to 17.2% (P0.001) and the clinical
endpoint at 6 months was reduced from 50% to 16.7% (P0.001), respectively. After 12
months the effect of DCB persisted (clinical endpoint 52.6% vs. 16.7%; p0.001 and TLR
36.8% vs. 15.3%, p0.005, respectively). There was one probable stent thrombosis in the
POBA group. Clinical follow-up after 2 years will be completed in May 2013 and presented.
Conclusions: Paclitaxel coated balloon angioplasty was superior to balloon angioplasty
alone for the treatment of instent-restenosis of drug-eluting stents. The favorable effects of
the DCB-therapy persisted over 12 months.
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Background: The aim of this study is to compare the safety and efficacy of Sirolimus
(SES), Paclitaxel (PES), Everolimus-eluting stent (EES) and SeQuent™ Please, a
drug-eluting balloon (DEB) on the outcome of patients with diffuse in-stent restenosis
(D-ISR) after bare metal stent (BMS) implantation.
Methods: A prospective analysis of 1078 patients with 1251 D-ISR lesions (427 SES,
363 PES, 232 EES and 229 DEB) in six high volume Asian centers after successful stent
implantation (SES: LAD 45.7%, LCX 27.9%, RCA 26.4%) (PES: LAD 46.0%, LCX
22.9%, RCA 31.1%) (EES: LAD 50.0%, LCX 21.0%, RCA 29.0%) (DEB: LAD 54.0%,
LCX 23.0%, RCA 23.0%) was performed. The study endpoints were major adverse
cardiac events (MACE) and target lesion revascularization (TLR) at 12 and 24 months.
Results: See table for clinical results.
Conclusions: (1) The use of SES, PES, EES and DEB in patients with D-ISR seems to
be favorable in terms of in-hospital clinical outcome. (2) Patients treated with DEB
showed higher restenosis rate and TLR compared with DES.
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Background: Effect of intravascular ultrasound (IVUS)-guided complex approaches
using drug-eluting stent (DES) for coronary bifurcation lesions on clinical outcome has
been not yet studied.The present study aimed to analyze the difference in one-year
outcome after two-stent techniques with the implantation of DES for coronary bifurcation
lesions between IVUS-guided versus angiography-guided groups.
Methods: From May 26, 2007 to March 24, 2010, 628 patients received two-stent
techniques (324 in IVUS-guided, 304 in Angio-guided group) were prospectively studied.
We compared the major adverse cardiac event (MACE, including cardiac death, stent
thrombosis [ST], myocardial infarction[MI], target lesion/vessel revascularization)at
12-month follow-up, before and after adjusting by using propensity score matching.
Results: By 12-month after indexed procedure, patients in the Angio-guided group had
significantly increased in-stent restenosis. The unadjusted late ST rate was 6.9%, 5.3%
and 4.3% in the Angio-guided group was 4.3%, significantly different to 0.6% in the
IVUS-guided group (p0.003),1.2% 0.6% and this translated into the significant
differences in overall (6.9% vs. 1.2%, p0.001) and definite (5.3% vs. 0.6%, p0.001)
ST, MI (8.9% vs. 4.6%, p0.038) and cardiac death (3.3% vs. 0.9%, p0.049) between
two groups. By propensity score matching, 123 paired patients were matched, the late ST
at 12-month follow-up was 4.9% in Angio-guided group, and it was 0% in the
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IVUS-guided group (p0.029), resulting in significant difference in ST-elevation MI
between two groups (9.8% vs. 2.4%, p0.030).
Conclusions: IVUS-guided two-stent techniques was associated with significantly
reduced late stent thrombosis, with resultant reduction of ST-elevation myocardial
infarction.
Table 7. Clinical follow-up after propensity score matching
IVUS-guided
(n123)
Angio-guided
(n123) p
In-hospital, n (%)
Stent thrombosis 2(0.6) 5(1.6) 0.272
Overall death 1(0.3) 3(1.0) 0.359
Cardiac 1(0.3) 3(1.0) 0.359
Myocardial infarction 12(3.7) 11(3.6) 1.000
STEMI 3(0.9) 6(2.0) 0.327
CABG 0 0 NS
TLR 0 1(0.3) 0.484
TVR 0 1(0.3) 0.484
MACE 12(3.7) 11(3.6) 1.000
Procedural success, n (%) 312(96.3) 293(96.4) 1.000
At 12-month
Stent thrombosis 1(0.8) 10(8.1) 0.010
definite 1(0.8) 9(7.3) 0.019
probable 0 1(0.8) 1.000
possible 0 0 NS
early 1(0.8) 4(3.3) 0.370
late 0 6(4.9) 0.029
Overall death 0 5(4.1) 0.060
Cardiac 0 4(3.3) 0.122
Myocardial infarction 4(3.3) 12(9.8) 0.067
STEMI 3(2.4) 12(9.8) 0.030
CABG 0 1(0.8) 1.000
TLR 13(10.6) 11(11.4) 1.000
TVR 14(11.4) 17(13.8) 0.701
MACE 20(16.3) 22(17.9) 0.866
IVUS, intravascular ultrasound; STEMI, ST-segment elevation myocardial
infarction; CABG, coronary artery bypass graft; TLR, target lesion
revascularization; TVR, target vessel revascularization; MACE, major adverse
cardiac event
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Background: Emerging data suggest that 2nd generation drug-eluting stents (DES) may
improve event-free survival compared to 1st generation DES. Whether or not this applies
to both sexes is unknown.
Methods: The SPIRIT II, III and IV randomized controlled trials (RCT) compared the
second-generation everolimus-eluting stent (EES) to the first-generation paclitaxel-eluting
stent (PES). Summary-level data of each study was pooled using meta-analytic tech-
niques. We evaluated the impact of gender on adverse events stratified by DES type.
Relative risks and 95% confidence intervals were calculated for the following outcomes:
definite or probable stent thrombosis (ST), target lesion revascularization (TLR), myo-
cardial infarction (MI), major adverse cardiovascular events (MACE) and cardiac death.
Results: Women (n1583, 31.7%), were older, more often diabetic and less likely to
have multivessel disease compared to men. After a weighted mean follow-up of 2.3 years,
among patients receiving PES, the incidence of MACE was significantly higher while
rates of MI and TLR were modestly higher among women (Figure). In contrast, MACE
rates were lower with EES than PES in both men and women, and outcomes were similar
in men and women receiving EES. Rates of ST (0.5% vs. 0.7%, p0.65) and cardiac
death (0.9% vs. 1.0%, p0.95) in EES-treated patients did not differ in women vs. men.
Conclusions: In this pooled analysis of RCT, adverse events were modestly higher among
women compared to men treated with PES. In contrast, outcomes were improved with EES
in both men and women such that female sex was no longer associated greater MACE.
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Background: Quantitative evaluation of collateral flow by coronary computed tomog-
raphy angiography (CCTA) has not been reported. We did a proof-of-concept study to
determine the extent or direction of CCTA.
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